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Abstract
Background and objective: The use of antibiotics in acute pancreatitis despite recent clinical
trials remains controversial. The aim of this study is to review the latest clinical trials and guidelines
about antibiotics in acute pancreatitis and determine its proper use.
Methods: Through a Medline search, we selected and analyzed pertinent randomized clinical trials
and guidelines that evaluated the use of antibiotics in acute pancreatitis. We answered the most
frequent questions about this topic.
Results and conclusion: Based on these clinical trials and guidelines, we conclude that the best
treatment currently is the use of antibiotics in patients with severe acute pancreatitis with more
than 30% of pancreatic necrosis. The best option for the treatment is Imipenem 3 × 500 mg/day
i.v. for 14 days. Alternatively, Ciprofloxacin 2 × 400 mg/day i.v. associated with Metronidazole 3 ×
500 mg for 14 days can also be considered as an option.
Review
Severe acute pancreatitis (SAP) as defined by the Atlanta
criteria, is present in up to 25% of patients with acute pan-
creatitis (AP) [1], with mortality of 10%–20%.
In these patients, AP develops in two phases: the first ten
days are characterized by the systemic inflammatory
response syndrome (SIRS), whereas in the end of the sec-
ond week infection complications begin to appear [2].
These complications due to infection are responsible for
up to 80% of deaths in patients with AP. About 40% to
75% of patients with pancreatic necrosis develop infec-
tion, 24% after the first week and 71% after the third week
[3,4], with mortality rates up to 50% [5,6]. The mecha-
nisms of infection in AP are bacteria translocation, via
lymphatic, via hematogenic, and reflux from duodenum
and biliary tree as well [7].
If the major problem in AP is infection of pancreatic
necrosis, it makes sense to consider that the use of antibi-
otics in this situation could reduce the morbidity and
mortality of these patients. However, at present there are
still controversies about this topic.
Therefore, some questions remain unclear regarding the
use of antibiotics in AP:
1-Should we use antibiotics in Acute Pancreatitis?
2-Which antibiotic?
3-How long?
4-Should we wait for more studies?
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1- Should we use antibiotics in Acute Pancreatitis?
SAP is characterized by the presence of organic failure
(Ranson ≥ 3 or APACHE II ≥ 8), or local complications
such as necrosis, pseudocyst and abscess [8-11].
The Balthazar score on CT scan determines the intensity of
local complications. The presence of pancreatic or peri-
pancreatic necrosis and fluid collections define AP as
locally severe [12,13].
Some authors observed reduction in necrosis infection
after the introduction of antibiotics in the treatment of
severe forms of AP, when compared with historic controls
without antibiotics. Banks et al. described a decrease from
67% to 32% [14], while Ho & Frey observed a reduction
from 75% to 20% in the infection of pancreatic necrosis
[15].
a. Review of clinical trials
There are few randomized clinical trials about the use of
antibiotics in AP. Pederzoli et al. in 1993 [16] conducted
the first of them, which analyzed 74 patients with SAP in
six medical centers in Italy. The patients were randomized
in two groups: one control with 33 patients and the treat-
ment group with 41 patients that received Imipenem 3 ×
500 mg/day intravenously (i.v.) during 14 days. They
observed reduction in pancreatic sepsis in patients that
received antibiotics (30.3% vs. 12.2%, p < 0.01). How-
ever, they did not find reduction in mortality between the
groups (12% vs. 7%, respectively).
Sainio et al. carried out another study in 1995 [17], ana-
lyzing data from 60 patients with SAP. One group control
and the other treated with Cefuroxime 3 × 1.5 g/day i.v.
They observed reduction in the number of pancreatic
operations (36 vs. 8, p = 0.012) and in mortality (7 vs. 1,
p = 0,028) in the treatment group. However, 66.7% of
patients in this group had their antibiotics changed during
the treatment. Furthermore, 23 out of 30 patients in the
control group received antibiotics in an average period of
six days after the beginning of the treatment. The use of
this cephalosporin is also questionable due to low pancre-
atic penetration.
Delcenserie et al. in 1996 [18] analyzed prospectively 23
patients with alcoholic SAP that were divided into two
groups: one control and one that was treated with Ceftazi-
dime 3 × 2 g/day i.v., Amicacin 2 × 7.5 mg/kg i.v., and
Metronidazole 3 × 500 mg i.v. for 10 days. They observed
a decrease in septic complications in the treatment group
(7 vs. 0, p = 0.03). Nevertheless, there was no difference in
mortality rate between the groups. In another clinical
trial, Schwarz et al. described a decrease in pancreatic
infection in a group of 29 patients, utilizing Ofloxacin and
Metronidazole (7% × 46%, respectively) [19].
In summary, the studies of Pederzoli, Delcenserie e
Schwarz demonstrated reduction in pancreatic infection,
although without decrease in mortality. Only Sainio
observed reduction in mortality with the use of antibiot-
ics. In spite of these results, a solid answer to the question
about the use of antibiotics in AP was still missing [1,20]
(Table 1).
In 2004, the Ulm group in Germany published the best
study regarding the use of antibiotics in AP [21]. It was a
prospective randomized double-blind trial that analyzed
114 patients, 58 that received antibiotics (Ciprofloxacin 2
× 400 mg/day i.v. + Metronidazole 2 × 500 mg/day i.v.)
and 56 that received placebo. It was established that if any
patient developed systemic inflammatory response,
organic failure, any kind of infection or clinical deteriora-
tion, this patient would be discontinued from the proto-
col with open antibiotic treatment. Their results showed
that the use of antibiotics did not reduce pancreatic infec-
tion (12% antibiotics vs. 9% placebo, p = n.s.) and mor-
tality (5% antibiotics vs. 7% placebo, p = n.s.). However,
28% of patients in the group that received antibiotics had
their protocol opened, versus 46% in the placebo group
(p = 0.037). Furthermore, the mean time to open the pro-
tocol was 11.5 days in the treatment group and 5 days in
the placebo group (Table 2). Based on these data, it is rea-
sonable to suppose that a group of patients had benefits
Table 1: Clinical studies comparing the use of antibiotics with placebo
Authors Treatment Patients (n) Infected necrosis (%) Mortality (%)
Pederzoli et al. [16] Imipenem 41 12* 7
P l a c e b o 3 33 01 2
Sainio et al. [17] Cefuroxime 30 30 3*
P l a c e b o 3 04 02 3
Delcenserie et al. [18] Ceftazidime + Amicacin + 
Metronidazole
11 0* 0
P l a c e b o 1 23 32 5
Schwarz et al. [19] Ofloxacin + Metronidazole 13 62 0
P l a c e b o 1 35 41 5World Journal of Emergency Surgery 2006, 1:20 http://www.wjes.org/content/1/1/20
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receiving early antibiotics. This is the same opinion of
other authors [22,23].
b. Time of infection
Although the risk for the development of pancreatic infec-
tion is higher in the third week, microorganisms can be
found in the pancreatic tissue in the first week [24].
De Souza et al. demonstrated in an experimental model
that bacteria could be detected in the pancreatic tissue six
hours after the induction of AP [25]. Similarly, Schwarz et
al. observed bacteria in the pancreatic necrosis between 8
and 16 hours after the pancreatitis induction [26].
These data suggest that the best time to introduce antibi-
otics is immediately after the diagnosis of AP and the eval-
uation of its severity. However, the confirmation of
necrotizing pancreatitis by CT scan can take at least 72
hours since the onset of symptoms. C-reactive protein is a
sensitive marker of pancreatic necrosis and it starts to
increase significantly 48 hours after the onset of symp-
toms. Thus, C-reactive protein can be useful in the identi-
fication of patients with high possibility to develop
necrosis, in particular when the value is over 150 mg/dl,
and subsequently define which patients are candidates to
receive early antibiotics [27].
Nordback et al, in a clinical trial observed advantages in
the early use of Imipenem in patients with pancreatic
necrosis when compared with the late use [28].
c. Complications of antibiotics in AP
The main arguments against the use of antibiotics are the
increase of fungal infection, and the increase of bacteria
resistance, with more Gram-positive infections [1].
There are evidences in the literature that fungal infection
has to be considered as an additional factor which influ-
ences the outcome of the patients [29].
One paper analyzing data of 46 patients with infected
pancreatic necrosis receiving antibiotics showed that 17
(37%) of them developed fungal infection. Nevertheless,
the fungal infection did not contribute to increase mortal-
ity in this group of patients [30].
Gloor et al. analyzed 103 patients with necrotizing AP that
received antibiotics (Imipenem/cilastatin) and concluded
that fungal infections when treated properly do not con-
tribute to a worst prognosis. This same paper showed that
the presence of multi-resistant bacteria was rare (2.9%)
[3].
d. Guidelines
Several guidelines about the treatment of AP can be found
in the literature, and the majority of them recommend the
early use of antibiotics in patients with pancreatic necrosis
(Table 3) [31-39]. The International Association of Pan-
creatology guidelines for the management of AP recom-
mends the use of prophylactic broadspectrum antibiotics
to reduce infection rates in CT-proven necrotizing pancre-
atitis as a recommendation grade A [31]. The Cochrane
review about the use of antibiotics in AP concluded that
despite variations in drug agent, duration of treatment
and methodological quality of clinical trials, there is
strong evidence that intravenous antibiotic prophylactic
therapy for 10 to 14 days decrease the risk of superinfec-
tion of necrotic tissue and mortality in patients with SAP
with proven pancreatic necrosis at CT [37].
Moreover, the UK guidelines for the management of AP
advocate that the risk of infected necrosis is very small
when there is less than 30% necrosis [34]. Although there
is no support in the literature, it is reasonable to assume
that prophylactic antibiotic therapy should be considered
only for patients with more than 30% pancreatic necrosis.
In contrast, there is no evidence in the literature that the
use of antibiotics in the absence of necrosis is beneficial.
Based on these studies we believe that the use of antibiot-
ics is benefic to patients with SAP with more than 30%
pancreatic necrosis, and starting as soon as possible.
2- Which antibiotic?
Two main aspects must drive the choice of the antibiotics:
the flora and the penetration in the pancreatic tissue.
Table 2: Results of a clinical double-blind trial about the use of antibiotics in severe acute pancreatitis [21]
Intention to treat (114 patients) Pancreatic necrosis (CT) (76 patients)
Treatment Ciprofloxacin/
Metronidazole (58 
patients)
Placebo (56 patients) Ciprofloxacin/
Metronidazole (58 
patients)
Placebo (56 patients)
Mortality 5% 7% 7% 11%
Surgical treatment 17% 11% 24% 19%
Necrosis infection 12% 9% 17% 14%
Protocol opened 28%* 46% 37% 57%World Journal of Emergency Surgery 2006, 1:20 http://www.wjes.org/content/1/1/20
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One single microorganism causes most of infections in
AP. The bacteria most frequently found are E. coli (27–
35%), Enterococcus (24–26%), Staphylococcus aureus
(14–16%), Staphylococcus epidermidis (15%), Klebsiella
(15%) Pseudomonas sp (7–11%) and Streptococos (4–
7%) [7,40,41].
Ampicillin was one of the first antibiotics used in AP,
although it has failed to show advantages to these
patients, due to poor action in the flora and low penetra-
tion in the pancreatic tissue [42].
Experimental studies were performed to determine which
antibiotic would have a better pancreatic concentration
[43,44]. Mithofer et al. in a necrotizing pancreatitis model
defined three groups: one treated with saline solution, the
second treated with Ciprofloxacin and the third treated
with Imipenem/cilastatin six hours after the induction of
AP. After seven days, 75% of the animals in the saline
group had infection, while 25% in the Imipenem group
(p < 0.01) and 6% in the Ciprofloxacin group (p < 0.01).
After 21 days, the infection rate was 71%, 33% and 35%
respectively (p = n.s.). The survival in seven days was 68%
in the control group, 60% in the Imipenem group (p =
0.071) and 43% in the Ciprofloxacin group (p < 0.01).
After 21 days, the survival was 23% in the control group
vs. 52% in the Imipenem group (p = 0.044) and 70% in
the Ciprofloxacin group (p < 0.001) [44].
Büchler et al, in 1992, developed a table about the efficacy
of several antibiotics, based on the pancreatic concentra-
tion of the antibiotic in patients undergone pancreatic
surgery (Table 4) [45]. The antibiotic with higher penetra-
tion was Imipenem, followed by Ciprofloxacin.
The pancreatic concentration of an antibiotic is deter-
mined by some factors: properties of the antibiotic, anat-
omy and physiology of the pancreas, alkaline pH, high
ion concentration, enzymatic and hormonal regulation,
pathologic changes and infection [45]. Spicak et al., stud-
ied experimentally the penetration of five antibiotics in
the pancreatic tissue of rats with AP, and observed that
Cefoperazone (3rd generation cephalosporin) and
Ofloxacin had adequate penetration, while Amoxicillin/
Clavulanic acid, Piperacillin and Amicacin demonstrated
insufficient penetration. They concluded that antibiotic
penetration was not influenced by necrosis of the pan-
creas [46].
In a clinical trial, Bassi et al. compared two groups with 30
patients each, whereas the first one received Pefloxacin,
and the second Imipenem. They observed a decrease in
the infection of pancreatic necrosis in the Imipenem
group (3 × 10, p = 0.034). There was no difference in mor-
tality (10% contra 24%, p = 0.18) [47]. This study showed
that Pefloxacin was less effective than Imipenem in clini-
cal practice. Although this is not a study comparing Cip-
roflofloxacin, it can suggest that antibiotics of this class
can be less effective than Imipenem.
Based on these studies and guidelines, we conclude that
the recommended antibiotic in AP is Imipenem 3 × 500
Table 3: Consensus recommendations about the use of antibiotics in acute pancreatitis
Consensus Origin Recommendation
Uhl et al. 2002 [31] International Association of Pancreatology 
(Pancreatology)
Yes
Toouli et al. 2002 [32] Journal of Gastroenterology and Hepatology Yes
Nathens et al. 2004 [33] Crit Care Med No
UK working party 2005 [34] United Kingdom (Gut) No consensus
Clancy et al. 2005 [35] Journal of Gastrointestinal Surgery Yes
Werner et al. 2005 [36] Gut Yes
Bassi et al. 2003 [37] Cochrane Yes
Chinese pancreatic disease group 2005 [38] Chinese society of gastroenterology (Chinese 
Journal of Digestive Diseases)
Yes
Takeda et al. 2006 [39] JPN Guidelines for the management of acute 
pancreatitis
Yes
Table 4: Penetration of antibiotics in the pancreatic tissue [45]
Poor penetration Medium penetration Good penetration
Netilmicin Mezlocillin Ciprofloxacin
Tobramicin Piperacillin Ofloxacin
Ceftizoxime Imipenem
Cefotaxime MetronidazoleWorld Journal of Emergency Surgery 2006, 1:20 http://www.wjes.org/content/1/1/20
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mg/day i.v. Alternatively, the use of Ciprofloxacin 2 × 400
mg/day i.v. associated with Metronidazole 3 × 500 mg/
day i.v. can also be considered.
3- How long?
There are no studies evaluating how long these patients
should be treated with antibiotics. This time is deter-
mined by consensus meetings that recommend a period
of 10 to 14 days [32,34,35,37,38]. After this period, each
patient must be evaluated individually to determine if the
antibiotics will be suspended, modified or continued. The
cultures for bacteria and fungus are fundamental in this
phase.
4- Should we wait for more studies?
Although there is no definitive conclusion about the use
of antibiotics in AP, strong evidences suggest that they are
beneficial. Isenmann's study is the more adequate about
the use of antibiotics, and despite of a negative conclu-
sion, it has shown that a group of patients deserved the
early use of antibiotics.
New studies are coming, hopefully with a greater number
of patients and more solid conclusions. However, we
should not wait for them to make a decision in the treat-
ment of these patients.
Conclusion
Based on available studies and in the guidelines opinions,
we conclude that the best policy currently is the use of
antibiotics in patients with SAP and more than 30% pan-
creatic necrosis. The antibiotic recommended is Imi-
penem 3 × 500 mg/day i.v. for 14 days. Alternatively,
Ciprofloxacin 2 × 400 mg/day i.v. associated with Metro-
nidazole 3 × 500 mg/day for 14 days can also be consid-
ered as an option.
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